• 1
    Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res 2010; 85: 5974.
  • 2
    Food and Drug Administration (FDA). FDA Approves Atazanavir, a Once Daily Protease Inhibitor for HIV Infection. 2003. Aivailable at (last accessed 22 February 2011).
  • 3
    European Medicines Agency (EMEA). EPAR summuray for public, Reyataz, atazanavir. 2010. Aivailable at (last accessed 22 February 2011).
  • 4
    Santoro MM, Bertoli A, Lorenzini P, Lazzarin A, Esposito R, Carosi G, Di Perri G, Filice G, Moroni M, Rizzardini G, Caramello P, Maserati R, Narciso P, Cargnel A, Antinori A, Perno CF. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the care study. AIDS Patient Care STDS 2008; 22: 716.
  • 5
    Giuntini R, Martinelli C, Ricci E, Vichi F, Gianellli E, Madeddu G, Abeli C, Palvarini L, Penco G, Marconi P, Grosso C, Pellicano G, Bonfanti P, Quirino T. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med 2010; 11: 405.
  • 6
    Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 32332.
  • 7
    Malan DR, Krantz E, David N, Rong Y, Mathew M, Lloeje UH, Jun S, McGrath D. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic Ill) 2010; 9: 3442.
  • 8
    World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. 2010. Available at (last accessed 22 February 2011).
  • 9
    Clinical Trials. Atazanavir used in combination with other anti-HIV drugs in HIV infected infants, children, and adolescents, no NCT00006604. 20002011. Available at (last accessed 22 February 2011).
  • 10
    Food and Drug Administration. New pediatric dosing recommendations for Reyataz Capsules, patients ages 6 to 18 years old. 2009. Available at (last accessed 22 February 2011).
  • 11
    European Medicines Agency (EMEA). EPAR summuray for public, Reyataz, atazanavir. 2006. Aivailable at (last accessed 4 April 2011).
  • 12
    Bristol-Myers Squibb. Reyataz™ (atazanavir sulfate) Capsules. 2003. Available at (last accessed 22 February 2011).
  • 13
    Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50: 38018.
  • 14
    Uglietti A, Stefano N, Gulminetti R, Maserati R. Correlations between atazanavir Ctrough and hyperbilirubinemia: a case report. J Med Case Reports 2009; 3: 9307.
  • 15
    European Medicines Agency (EMEA). Reyataz: EPAR – product information. 2010. Available at (last accessed 22 February 2011).
  • 16
    Bristol-Myers Squibb. REYATAZ: highlights of prescribing information. 2010. Available at (last accessed 22 February 2011).
  • 17
    Gilead Sciences, Inc. Viread (Tenofovir Disoproxil Fumarate) Tablet: Highlights of Prescribing Information. Foster City, CA: Gilead Sciences, Inc., 2010.
  • 18
    Macassa E, Delaugerre C, Teglas JP, Jullien V, Treluyer JM, Veber F, Rouzioux C, Blanche S. Change to once-daily combination including boosted atazanavir in HIV-1 infected children. Pediatr Infect Dis J 2006; 25: 80914.
  • 19
    Beal SL, Sheiner LB. NONMEM User's Guide. NONMEM project group, San Francisco, CA: University of California, 1992.
  • 20
    Ahn JE, Karlson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008; 35: 40121.
  • 21
    Anderson BJ, Holford NHG. Mechanism-based- concepts of size and maturity in pharmacokinetics. Annu Rev Toxicol 2008; 48: 30332.
  • 22
    Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 15466.
  • 23
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computin, 2009.
  • 24
    Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 333642.
  • 25
    Seminari E, Guffanti M, Villani P, Gianotti N, Cusato M, Fusetti G, Galli A, Castagna A, Regazzi M, Lazzarin A. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol 2005; 61: 5459.
  • 26
    Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother 2009; 64: 10719.
  • 27
    Dailly A, Tribut O, Tattevin P, Arvieux C, Perre P, Raffi F, Jolliet P. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir patients. Eur J Clin Pharmacol 2006; 62: 5236.
  • 28
    Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Journal of Antimicrobial. Chemotherapy 2009; 63: 123343.
  • 29
    Solas C, Gagnieu MC, Ravaux I, Drogoul MP, Lafeuillade A, Mokhtari S, Lacarelle B, Simon N. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit 2008; 30: 6703.
  • 30
    Food and Drug Administration. New information about treatment of Latent Tuberculosis Infection in HIV infected and Uninfected Individuals. 2003. Available at (last accessed 22 February 2011).
  • 31
    Taburet AM, Piketty C, Gerard L, Vincent L, Chazallon C, Clavel F, Calvez V, Aboulker JP, Girard PM. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovirin hiv infected patients with multiple treatment failures: a sub-study of puzzle2-ANRS 107 Trial. Conf Retroviruses Opportunistic Infect 2003; 10th: abstract no. 537.
  • 32
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011; 1–166. Available at (last accessed 22 February 2011).
  • 33
    European Medicines Agency (EMEA). Reyataz: EPAR – assesment report – variation. 2010. Available at (last accessed 22 February 2011).
  • 34
    Zhu L, Liao S, Child M, Sevinsky H, Eley T, Wang Y, Xu X, Mathew M, McGrath D, Bertz R. CASTLE Study: pharmacokinetics and inhibitory quotient of Atazanavir/ritonavir 300/100 mg once daily compared to Lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment-naive subjects. 9th International Workshop on Pharmacology of HIV Therapy, New Orleans, LA 2008. Available at (last accessed 22 February 2011).